Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Climb Bio, Inc.NASDAQ: CLYM
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $9.34M fell 46.1% year over year, ahead of the -52.9% change in trailing-twelve-month research & development. Sequentially, it fell 32.0% from the prior quarter. Over 3 fiscal years it compounded at +21.2% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -46.1% holds above the trailing-twelve-month pace of -52.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 46.62M USD
- Year-over-year change
- +225.2%
- 4-year CAGR
- +18.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.62M | +225.2% |
| FY2024 | 2024-12-31 | 14.34M | -7.0% |
| FY2023 | 2023-12-31 | 15.41M | -41.2% |
| FY2022 | 2022-12-31 | 26.21M | +12.4% |
| FY2021 | 2021-12-31 | 23.32M | — |
Research & Development vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 research & development of $38.72M is the lowest of the 5 companies compared; the peer median is $143.59M.
- Its year-over-year change of -52.9% is the lowest of 5, against a peer median of +32.6%.
- Over three fiscal years its annual growth of +21.2% compares with a peer median of +53.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.01M | +44.8% | +53.7% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $147.57M | +91.5% | +94.3% | 4442.3% |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $38.72M | -52.9% | +21.2% | — |
| Peer median (excluding CLYM) | $143.59M | +32.6% | +53.7% | 4442.3% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 97K |
| Gross Profit | 0 | 0 | 0 | 0 | (97K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.32M | 26.21M | 15.41M | 14.34M | 46.62M |
| Selling, General & Admin | 12.35M | 18.92M | 24.86M | 16.03M | 21.17M |
| Operating Expenses | 35.67M | 45.14M | 40.28M | 82.02M | 67.79M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| EBITDA | (47.48M) | (45.24M) | (35.12M) | (30.36M) | (59.75M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.67M) | (45.14M) | (40.28M) | (82.02M) | (67.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.38M | 4.62M | 8.13M | 8.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11.81M) | (109K) | 5.16M | 8.12M | 8.03M |
| Income Before Tax | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| EPS (Diluted) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| Weighted Avg Shares | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
| Weighted Avg Shares (Diluted) | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.